Unknown Analyst

From Mineralys, I have here with me today, Jon Congleton. Jon, thanks for joining us. I'm just going to hand it over to Jon for some opening remarks before we dive into some Q&A.

Jon Congleton
President, CEO & Director

Thanks, Dina. I appreciate it. Appreciate the opportunity to participate in the Bank of America conference. It was a positive conference for us. So Jon Congleton, CEO of Mineralys. We had a very productive 1.5 years, I would say, last year with a lot of data readouts culminating in the submission. We had an earnings call last week announced that in Q1, we had the acceptance of the NDA, significant milestone for Mineralys. It puts us one step closer to getting lorundrostat to patients who fundamentally need this drug. That NDA, very proud of what the team put together, it's very distinct and differentiated data set that is going in front of the FDA for review effectively five clinical trials showing very consistent robust benefit that lorundrostat has on blood pressure, safely predict profile that I think fits easily into the current use case that physicians have for those uncontrolled and resistant -- is that better?

Unknown Executive

So obviously, only you in the room got the opening preamble. So that data set, to me, is very important because it speaks to the 20 million patients in the United States that are on two or more meds and can I get to goal. For those of you that have met me in the past, you know I started my career as a sales rep in the hypertension space.

And